Confirmed: Chimerix’s $45 Million Fundraising
As peHUB.com reported late last week, Chimerix Inc., the pharmaceutical drug company working on orally-available antiviral therapeutics has completed a $45 million fundraising. New investors include Pappas Ventures and Morningside Group; other investors include Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.
14 February 2011•4 mins read
